Sanofi (SNY) Cost of Revenue (2009 - 2026)

Sanofi has disclosed Cost of Revenue across 18 years of filings, most recently posting $3.7 billion for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.7 billion, up 20.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.1 billion (up 35.71% YoY), and the FY2025 annual result was $15.2 billion, up 7.65% from the prior year.
• Cost of Revenue came in at $3.7 billion for Q1 2026 at Sanofi, down from $15.2 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $15.2 billion in Q4 2025 to a low of $3.0 billion in Q1 2025.
• The 5-year median for Cost of Revenue is $3.7 billion (2026), against an average of $5.9 billion.
• Across the five-year window, Cost of Revenue slumped 72.83% in 2022 and surged 256.65% in 2023, its largest moves.
• Sanofi's Cost of Revenue stood at $3.8 billion in 2022, then soared by 256.65% to $13.6 billion in 2023, then advanced by 3.86% to $14.1 billion in 2024, then grew by 7.65% to $15.2 billion in 2025, then tumbled by 75.81% to $3.7 billion in 2026.
• The last three Cost of Revenue figures came in at $3.7 billion (Q1 2026), $15.2 billion (Q4 2025), and $10.9 billion (Q3 2025), per Business Quant data.